Editorial Standards

Latest News Today maintains rigorous editorial standards. Our team verifies information from trusted sources and provides context to help readers understand complex stories.

Last Updated: Thursday, October 1, 2026 at 07:11 PM
Category: Id

Editor's Note

Latest News Today provides comprehensive coverage and analysis of breaking news stories. This article is part of our ongoing coverage of wbna8929639, bringing you verified information from trusted sources with added context and expert perspective.

Why This Matters: Understanding the full context of this story helps readers make informed decisions and stay updated on developments that impact our community.

Cannabis drugs might relieve bowel disease

Derivatives of the active compound in cannabis — cannabinoids — may have the potential for treating inflammatory bowel diseases like Crohn’s disease and ulcerative colitis, UK researchers report.

Derivatives of the active compound in cannabis — cannabinoids — may have the potential for treating inflammatory bowel diseases like Crohn’s disease and ulcerative colitis, UK researchers report.

“The system that responds to cannabis in the brain is present and functioning in the lining of the gut,” lead researcher Dr. Karen Wright, of the University of Bath, explained to Reuters Health. “There is an increased presence of one component of this system during inflammatory bowel diseases,” she explained.

Wright and her colleagues established the location of cannabinoid receptors CB1 and CB2 in human colon tissue, and used human colon cell lines to investigate the binding of cannabinoid compounds and in wound-healing experiments. They report their findings in the journal Gastroenterology

The team found that CB2 was increased in colonic tissue characteristic of inflammatory bowel disease. Cannabinoids enhanced surface wound closure via CB1-related mechanisms.

“Cannabinoids, which we make ourselves, as well as synthetic cannabinoids, can promote wound healing in the gut, which is extremely interesting given that inflammatory bowel disease involves damaged gut linings,” Wright said.

Although results are available yet, she added, relevant studies of the use of cannabinoids are taking place in the UK and a clinical trial is being conducted in Germany.